- Home
- RPRX vs HLI Comparison
RPRX vs HLI Comparison
Compare RPRX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | HLI |
|---|---|---|
| Founded | 1996 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 14.4B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RPRX | HLI |
|---|---|---|
| Price | $40.54 | $183.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | $45.75 | ★ $202.63 |
| AVG Volume (30 Days) | ★ 3.4M | 410.9K |
| Earning Date | 02-11-2026 | 01-28-2026 |
| Dividend Yield | ★ 2.33% | 1.29% |
| EPS Growth | N/A | ★ 26.59 |
| EPS | 1.75 | ★ 6.19 |
| Revenue | $2,349,844,000.00 | ★ $2,565,361,000.00 |
| Revenue This Year | $37.66 | $15.36 |
| Revenue Next Year | $2.34 | $13.10 |
| P/E Ratio | ★ $23.06 | $30.09 |
| Revenue Growth | 3.70 | ★ 21.00 |
| 52 Week Low | $29.66 | $137.99 |
| 52 Week High | $41.70 | $211.78 |
Technical Indicators
Market Signals| Indicator | RPRX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 59.05 | 49.76 |
| Support Level | $38.86 | $184.29 |
| Resistance Level | $40.58 | $195.06 |
| Average True Range (ATR) | 0.76 | 4.99 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 58.63 | 29.46 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.